November 3rd, 2010
Paricalcitol Reduces Albuminuria in Diabetic Nephropathy
Larry Husten, PHD
Selective vitamin D receptor activation with paricalcitol may help prevent progression of renal failure in patients with diabetic nephropathy who are already taking renin-angiotensin-aldosterone system (RAAS) inhibitors, according to a new study published online in the Lancet. In the VITAL study, U.S. and European investigators randomized 281 patients with type 2 diabetes and albuminuria who were […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?